83 related articles for article (PubMed ID: 22413512)
21. Effect of RU486 on hepatic and adipocyte gene expression improves diabetes control in obesity-type 2 diabetes.
Taylor AI; Frizzell N; McKillop AM; Flatt PR; Gault VA
Horm Metab Res; 2009 Dec; 41(12):899-904. PubMed ID: 19670152
[TBL] [Abstract][Full Text] [Related]
22. The role of dysregulated glucagon secretion in type 2 diabetes.
D'Alessio D
Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():126-32. PubMed ID: 21824266
[TBL] [Abstract][Full Text] [Related]
23. Analysis of gene expression profiles in insulin-sensitive tissues from pre-diabetic and diabetic Zucker diabetic fatty rats.
Suh YH; Kim Y; Bang JH; Choi KS; Lee JW; Kim WH; Oh TJ; An S; Jung MH
J Mol Endocrinol; 2005 Apr; 34(2):299-315. PubMed ID: 15821098
[TBL] [Abstract][Full Text] [Related]
24. Effects of bis(alpha-furancarboxylato)oxovanadium(IV) on glucose metabolism in fat-fed/streptozotocin-diabetic rats.
Niu Y; Liu W; Tian C; Xie M; Gao L; Chen Z; Chen X; Li L
Eur J Pharmacol; 2007 Oct; 572(2-3):213-9. PubMed ID: 17651728
[TBL] [Abstract][Full Text] [Related]
25. Association of insulin resistance with hyperglycemia in streptozotocin-diabetic pigs: effects of metformin at isoenergetic feeding in a type 2-like diabetic pig model.
Koopmans SJ; Mroz Z; Dekker R; Corbijn H; Ackermans M; Sauerwein H
Metabolism; 2006 Jul; 55(7):960-71. PubMed ID: 16784971
[TBL] [Abstract][Full Text] [Related]
26. Effect of hyperinsulinemia and type 2 diabetes-like hyperglycemia on expression of hepatic cytochrome p450 and glutathione s-transferase isoforms in a New Zealand obese-derived mouse backcross population.
Pass GJ; Becker W; Kluge R; Linnartz K; Plum L; Giesen K; Joost HG
J Pharmacol Exp Ther; 2002 Aug; 302(2):442-50. PubMed ID: 12130701
[TBL] [Abstract][Full Text] [Related]
27. Prevention of hyperglycemia in Zucker diabetic fatty rats by exercise training: effects on gene expression in insulin-sensitive tissues determined by high-density oligonucleotide microarray analysis.
Colombo M; Gregersen S; Kruhoeffer M; Agger A; Xiao J; Jeppesen PB; Orntoft T; Ploug T; Galbo H; Hermansen K
Metabolism; 2005 Dec; 54(12):1571-81. PubMed ID: 16311088
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of the progression of type 2 diabetes in the C57BL/6J mouse model by an anti-diabetes herbal formula.
Winters WD; Huo YS; Yao DL
Phytother Res; 2003 Jun; 17(6):591-8. PubMed ID: 12820223
[TBL] [Abstract][Full Text] [Related]
29. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
30. Insulin resistance at the crossroads of metabolic syndrome: systemic analysis using microarrays.
Kim E
Biotechnol J; 2010 Sep; 5(9):919-29. PubMed ID: 20669253
[TBL] [Abstract][Full Text] [Related]
31. Effects of eicosapentaenoic acid on serum levels of selenoprotein P and organ-specific insulin sensitivity in humans with dyslipidemia and type 2 diabetes.
Takeshita Y; Teramura C; Kamoshita K; Takayama H; Nakagawa H; Enyama Y; Ishii KA; Tanaka T; Goto H; Nakano Y; Osada S; Tanaka Y; Tokuyama K; Takamura T
J Diabetes Investig; 2022 Mar; 13(3):532-542. PubMed ID: 34670012
[TBL] [Abstract][Full Text] [Related]
32. Current and future treatment strategies for type 2 diabetes: the beta-cell as a therapeutic target.
Tyrberg B; Levine F
Curr Opin Investig Drugs; 2001 Nov; 2(11):1568-74. PubMed ID: 11763159
[TBL] [Abstract][Full Text] [Related]
33. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin.
Kobayashi M; Ikegami H; Fujisawa T; Nojima K; Kawabata Y; Noso S; Babaya N; Itoi-Babaya M; Yamaji K; Hiromine Y; Shibata M; Ogihara T
Diabetes; 2007 Jan; 56(1):239-47. PubMed ID: 17192488
[TBL] [Abstract][Full Text] [Related]
34. Hepatokines: unlocking the multi-organ network in metabolic diseases.
Iroz A; Couty JP; Postic C
Diabetologia; 2015 Aug; 58(8):1699-703. PubMed ID: 26032022
[TBL] [Abstract][Full Text] [Related]
35. Energy restriction prevents the development of type 2 diabetes in Zucker diabetic fatty rats: coordinated patterns of gene expression for energy metabolism in insulin-sensitive tissues and pancreatic islets determined by oligonucleotide microarray analysis.
Colombo M; Kruhoeffer M; Gregersen S; Agger A; Jeppesen P; Oerntoft T; Hermansen K
Metabolism; 2006 Jan; 55(1):43-52. PubMed ID: 16324918
[TBL] [Abstract][Full Text] [Related]
36. [Differential diagnosis of diabetes mellitus caused by liver cirrhosis and other type 2 diabetes mellitus].
Kim MG; Choi WC
Korean J Hepatol; 2006 Dec; 12(4):524-9. PubMed ID: 17237630
[TBL] [Abstract][Full Text] [Related]
37. Hypoglycemic effect of protopanaxadiol-type ginsenosides and compound K on Type 2 diabetes mice induced by high-fat diet combining with streptozotocin via suppression of hepatic gluconeogenesis.
Li W; Zhang M; Gu J; Meng ZJ; Zhao LC; Zheng YN; Chen L; Yang GL
Fitoterapia; 2012 Jan; 83(1):192-8. PubMed ID: 22056666
[TBL] [Abstract][Full Text] [Related]
38. Hepatokines and metabolism: Deciphering communication from the liver.
Jensen-Cody SO; Potthoff MJ
Mol Metab; 2021 Feb; 44():101138. PubMed ID: 33285302
[TBL] [Abstract][Full Text] [Related]
39. Feeding-induced hepatokines and crosstalk with multi-organ: A novel therapeutic target for Type 2 diabetes.
Chen RB; Wang QY; Wang YY; Wang YD; Liu JH; Liao ZZ; Xiao XH
Front Endocrinol (Lausanne); 2023; 14():1094458. PubMed ID: 36936164
[TBL] [Abstract][Full Text] [Related]
40. Selenoprotein P as a significant regulator of pancreatic β cell function.
Saito Y
J Biochem; 2020 Feb; 167(2):119-124. PubMed ID: 31373634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
